(19)
(11) EP 4 798 585 A2

(12)

(88) Date of publication A3:
08.05.2025

(43) Date of publication:
02.09.2026 Bulletin 2026/36

(21) Application number: 24768738.7

(22) Date of filing: 09.08.2024
(51) International Patent Classification (IPC): 
C07D 417/14(2006.01)
A61K 31/433(2006.01)
 C07D 471/04(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 417/14; A61P 35/00; C07D 471/04; C07D 491/107
(86) International application number:
PCT/US2024/041747
(87) International publication number:
WO 2025/035108 (13.02.2025 Gazette 2025/07)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 10.08.2023 US 202363518738 P
11.06.2024 US 202463658747 P

(71) Applicant: ARase Therapeutics Inc.
Boston, MA 02125 (US)

(72) Inventors:
  • CHANG, Paul
    Boston, Massachusetts 02125 (US)
  • WIDDOWSON, Katherine
    Boston, Massachusetts 02125 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)

   


(54) {3-[5-(DIFLUOROMETHYL)-1,3,4-THIADIAZOL-2-YL]-2-OXO-1,3-DIHYDRO-1.3-BENZIMIDAZOL-5-YLSULFONYL}(3-METHYL-3-OXETANYL)AMINE DERIVATIVES AND SIMILAR COMPOUNDS AS PARG INHIBITORS FOR THE TREATMENT OF CANCER